Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses

Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 4, 2004, Pages 470-478

  Sugiura, Saiko ^a   Goshima, Fumi ^a   Takakuwa, Hiroki ^a   Sata, Tetsutaro ^b   Nakashima, Tsutomu ^a   Nishiyama, Yukihiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; FEMALE; HERPES SIMPLEX VIRUS; IMMUNOCOMPETENT CELL; MOUSE; NECK TUMOR; NONHUMAN; SARCOMA; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION;

EID: 1942446145     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2004.01.001     Document Type: Article

References (20)

1. Larson DL, Lindberg RD, Lane E; et al. Major complications of radiotherapy in cancer of the oral cavity and oropharynx. A 10 year retrospective study. Am J Surg 1983;146:531-6.
2. Breakefield XO, Kramm CM, Chiocca EA, et al. Herpes simplex virus vectors for the tumor therapy. In: Sobel RE, Scanlon KJ, editors. The Internet book of gene therapy. Cancer therapeutics. Hartford: Appleton & Lange; 1995. pp 41-56.
3. Boviatsis EJ, Scharf JM, Chase M, et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1994;1:323-31.
4. Mckie EA, MacLean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours: evaluation of a potentially effective clinical therapy. Br J Cancer 1996;74:745-52.
5. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002;62:2306-12.
6. Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003;148: 813-25.
7. Inagaki-Ohara K, Iwasaki T, Watanabe D, et al. Effect of the deletion of US2 and US3 from herpes simplex virus type 2 on immune responses in the murine vagina following intravaginal infection. Vaccine 2002;20:98-104.
8. Daikoku T, Yamashita Y, Tsurumi T, et al. Purification and biological characterization of the protein kinase encoded by the US3 gene of herpes simplex virus type 2. Virology 1993;197:685-94.
9. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988;62:196-205.
10. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967;26:365-9.
11. Sata T, Kurata T, Aoyama Y, et al. Analysis of viral antigens in giant cells of measles pneumonia by immunoperoxidase method. Virchow Arch A Pathol Anat Histopathol 1986;410:133-8.
12. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-6.
13. Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000;74: 3832-41.
14. Becker Y, Hardar J, Tabor E, et al. A sequence in HpaI-P fragment of herpes simplex virus-1 DNA determines intraperitoneal virulence in mice. Virology 1986;149: 255-9.
15. Berkowitz C, Moyal M, Rosen-Wölff A, et al. Herpes simplex virus type 1 UL56 gene is involved in viral intrapenitoneal pathogenicity to immunocompetent mice. Arch Virol 1994;134:73-83.
16. Koshizuka T, Goshima F, Takakuwa H, et al. Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 2002;76:6718-28.
17. Jerome KR, Fox R, Chen Z, et al. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol 1999;73:8950-7.
18. Ribas A, Bui LA, Butterfield LH, et al. Antitumor protection using murine dendritic cells pulsed with acideluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res 1999;19:1165-70.
19. Kimata H, Takakuwa H, Goshima F, et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 2003;50:961-6.
20. Aita K, Irie H, Koyama AH, et al. Acute adrenal infection by HSV-1: role of apoptosis in viral replication. Arch Virol 2001;146:2009-20.